SCHEMBL24463541

SCHEMBL24463541

Cc1cc2c(cc1I)ncn2C1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.41
DRD2 P14416 1/20 0.40
SLC6A4 P31645 1/20 0.40
USP2 O75604 1/20 0.39
GAA P10253 2/20 0.38
HSD17B10 Q99714 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRL1 P41146 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
TP53 P04637 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ATM Q13315 1/20 0.36
NPC1 O15118 1/20 0.35
PRKCI P41743 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30461540 0.80 HSD17B10 (0.38) DRD2SLC6A4USP2GAAHSD17B10
SCHEMBL24463284 0.80 IDO1 (0.42) DRD2SLC6A4GAAHSD17B10OPRM1
SCHEMBL24463271 0.80 HSD17B10 (0.38) DRD2SLC6A4USP2GAAHSD17B10
SCHEMBL4743122 0.78 DRD2 (0.44) CYP17A1DRD2SLC6A4USP2GAA
SCHEMBL15748917 0.75 EGFR (0.40) CYP17A1DRD2SLC6A4GAAHSD17B10
SCHEMBL24463569 0.74 GAA (0.43) DRD2SLC6A4GAAHSD17B10OPRM1
SCHEMBL24463552 0.74 GAA (0.43) DRD2SLC6A4GAAHSD17B10OPRM1
SCHEMBL17678349 0.72 GAA (0.50) CYP17A1DRD2SLC6A4USP2GAA
SCHEMBL24463038 0.72 GAA (0.50) DRD2SLC6A4GAAHSD17B10OPRM1
SCHEMBL23638516 0.72 FGFR1 (0.47) CYP17A1DRD2SLC6A4GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases KINNATE BIOPHARMA INC. (US) 2022-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 CYP17A1 2427/4885DRD2 4877/4885SLC6A4 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.